This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder

This study has been terminated.
(the study has concluded normally;)
Information provided by:
University Hospital, Rouen Identifier:
First received: September 13, 2005
Last updated: March 23, 2015
Last verified: March 2015
The purpose of this study is to determine the efficacy and tolerance of 2 dosages (750 versus 500 units) of the Dysport type A botulinic toxin for patient suffering from neurogenic urinary incontinence by an overactive bladder and the failure of anticholinergic drugs.

Condition Intervention Phase
Overactive Bladder Drug: type A botulinum toxin Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of the Efficacy and Tolerance of 2 Dosages of Type A Botulinic Toxin in Neurogenic Areactive Bladder Resistant to Oral Medical Treatment

Resource links provided by NLM:

Further study details as provided by University Hospital, Rouen:

Primary Outcome Measures:
  • complete urinary continence at baseline, and days 30, 90, 180, and 360

Secondary Outcome Measures:
  • number of mictions or self catheterizations a day
  • number of leakages, urgency adverse events
  • guarding times
  • urodynamics: bladder capacity, reflex volume, residual maximal capacity detrusor pressure, flow detrusor pressure

Enrollment: 80
Study Start Date: December 2003
Study Completion Date: October 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Neurogenic urinary incontinence with urodynamic overactivity resistant to anticholinergic

Exclusion Criteria:

  • Pregnancy
  • Bladder cancer
  • Symptomatic urinary infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00213577

Rouen, France, 76031
Sponsors and Collaborators
University Hospital, Rouen
Principal Investigator: Philippe GRISE, MD CHU de Rouen
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00213577     History of Changes
Other Study ID Numbers: 2003/112/HP
Study First Received: September 13, 2005
Last Updated: March 23, 2015

Keywords provided by University Hospital, Rouen:
overactive neurogenic bladder

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Botulinum Toxins
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs processed this record on August 18, 2017